Aurinia Pharmace Stock Price, News & Analysis

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will release its financial and operational results for Q4 and full year 2023 on February 28, 2023, before market opening. A conference call/webcast is scheduled for 8:30 am ET the same day to discuss these results and offer a business update. Participants can join by dialing 877-407-9170 or accessing the audio webcast on Aurinia's website. The company, headquartered in Victoria, British Columbia, focuses on therapies for serious diseases, having launched LUPKYNIS® in January 2021, the first oral treatment approved by the FDA for active lupus nephritis.

Aurinia Pharmaceuticals announced the grant of inducement stock options and restricted stock units (RSUs) to 7 new employees. The options allow the purchase of 70,070 common shares at $9.05 each, the closing price on February 3, 2023. These inducements are in accordance with Nasdaq Listing Rule 5635(c)(4) and mark a strategic move to attract talent. The stock options have a 10-year term, vesting over three years, while the RSUs will vest in three equal annual installments. Aurinia continues to focus on therapies for diseases with high unmet medical needs, including its FDA-approved treatment for lupus nephritis.

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced that the Patent Trial and Appeal Board (PTAB) has terminated the Inter Partes Review (IPR) related to its U.S. Patent No. 10,286,036. This patent is associated with LUPKYNIS, the first FDA-approved oral therapy for lupus nephritis (LN), a serious condition affecting many patients with systemic lupus erythematosus (SLE). With approximately 200,000-300,000 individuals in the U.S. diagnosed with SLE, around 50% may develop LN, emphasizing the therapeutic importance of LUPKYNIS for these patients.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced the allowance of a new patent for its product LUPKYNIS by the US Patent and Trademark Office, enhancing its dosing regimen for lupus nephritis treatment. This patent, along with a similar notice from the European Patent Office, could protect LUPKYNIS until 2037, extending its market exclusivity. The patent specifics align with FDA guidelines and aim to improve patient outcomes through precise eGFR-based dosing. CEO Peter Greenleaf emphasized the importance of this intellectual property in strengthening their market position.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) reported preliminary unaudited net revenues of approximately $28.4 million for Q4 2022, totaling $134.0 million for the full year. Net product revenues were around $28.3 million and $103.5 million respectively. The company reiterates its 2023 net product revenue guidance forecast of $120-$140 million. As of December 31, 2022, Aurinia held approximately $388.7 million in cash and equivalents. The number of patients on LUPKYNIS therapy increased to 1,525 by year-end.

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced that Peter Greenleaf, CEO, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11 at 4:30 p.m. PT in San Francisco, CA. Interested parties can listen to the live audio webcast on the Aurinia corporate website under the 'News/Events' section. Aurinia is dedicated to developing therapies for serious diseases, having launched LUPKYNIS®, the first FDA-approved oral treatment for active lupus nephritis in January 2021.

Aurinia Pharmaceuticals (NASDAQ: AUPH) and Sun Pharmaceuticals have reached a settlement regarding patent infringement claims related to Sun's CEQUA^® product. The settlement includes a joint motion to dismiss an Inter Partes Review of Aurinia's U.S. Patent No. 10,286,036. This agreement is contingent on the U.S. Patent Trial and Appeal Board terminating the Inter Partes Review. Both companies will cease further claims against each other under this settlement.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) announced the grant of inducement stock options and restricted stock units (RSUs) to two new employees. A total of 36,220 stock options were issued, with an exercise price of $5.10, alongside 22,120 RSUs, all dated December 5, 2022. The options vest over three years, while the RSUs vest in equal annual installments over three years. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent to support the company's mission in autoimmune disease therapeutics.

Aurinia Pharmaceuticals has received marketing authorization for LUPKYNIS (voclosporin) from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with active lupus nephritis (LN). This approval follows the European Commission's authorization on September 19, 2022, highlighting the drug's promising phase 3 clinical trial outcomes. LUPKYNIS is the first oral medication approved in both the U.S. and Europe for LN, aiming to improve treatment accessibility for patients.